Stay updated on Pembrolizumab in HER2+ Gastric Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.

Latest updates to the Pembrolizumab in HER2+ Gastric Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now shows recruitment is closed ('No longer looking for participants'); it also adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention label to Intervention/Treatment as well as the revision tag to v3.6.0.SummaryDifference0.1%

- Check15 days agoChange DetectedUpdated the page revision from v3.5.4 to v3.5.5, indicating a new version of the record. This reflects backend/editorial updates rather than changes to the trial data or public information.SummaryDifference0.0%

- Check22 days agoChange DetectedUkraine location data was updated. A new Kharkiv Oblast entry was added and the Kharkiv location now lists Kharkiv, Kharkiv Oblast, Ukraine, 61070, replacing the Kharkivs’ka Oblast’ designation.SummaryDifference0.0%

- Check37 days agoChange DetectedThe page revision history was updated: a new Revision: v3.5.4 was added and the previous Revision: v3.5.3 was removed. This update records a small metadata/version bump to the page, not altering study content or functionality.SummaryDifference0.0%

- Check58 days agoChange DetectedThe page footer revision number is updated from v3.5.2 to v3.5.3, reflecting a website build/version change rather than any modification to the study details.SummaryDifference0.0%

- Check65 days agoChange DetectedTemuco, Chile location updated from 'Temuco, Región de la Araucanía, Chile, 4780000' to 'Temuco, Araucania, Chile, 4780000'. Revision tag updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in HER2+ Gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.